PARP1 and neoplasm: Indeed, in the small cell lung cancer mouse model, PARP or CHK1 inhibition significantly potentiated the anti-tumor effect of PD-L1 blockade via STING mediated IRF3 activation, thereby inducing type I IFNs production and innate immune activation.139